These findings reinforce the growing clinical utility of HE4 in combination with CA125, as recently reported by different studies, which concluded that dual-marker strategies significantly increase diagnostic sensitivity and specificity for early-stage ovarian cancer compared with CA125 alone [61,62,63,64,65]. This evidence concerns the gene WFDC2 and ovarian carcinoma.